stockrow
Friday 6 November 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
- EPS
- +58.7%
- Free cash flow
- −24.3%
Quarter to June 2026, against a year earlier
4.26
0.02
+0.47%
Follow CING
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (198.74%) | (225.11%) | (450.60%) | (288.93%) |
+8 more TTM periods Free account |
|
| (123.76%) | (128.82%) | (149.98%) | (185.97%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(124.06%) | (149.91%) | (656.13%) | (691.08%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.59) | (2.02) | (3.48) | (3.28) | |
Free Cash Flow |
(20.94) | (19.77) | (17.61) | (17.79) | |
Capital Expenditures |
(0.28) | (0.22) | (0.36) | (0.06) | |
| Other line items | |||||
Cash ROIC |
(40.37%) | (44.18%) | (120.47%) | (185.47%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.72 | 0.70 | 0.77 | 0.79 | |
Depreciation/Fixed assets |
0.20 | 0.27 | 0.33 | 0.36 | |
Capex/Depreciation |
(0.88) | (0.49) | (0.64) | (0.11) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.57) | (2.00) | (3.41) | (3.26) | |
Capex per Share |
(0.02) | (0.02) | (0.07) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026